RBC Capital on Bristol-Myers Squibb Co. (BMY): 'Strong Execution Expected But May be Overshadowed by Key Binary Catalyst'

October 19, 2026 9:28 AM

RBC Capital analyst Trung Huynh reiterated a Sector Perform rating and $64.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

RBC Capital on Bristol-Myers Squibb Co. (BMY): 'Strong Execution Expected But May be Overshadowed by Key Binary Catalyst'

Categories